Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Press Enter ↵ to search evidence



    Explore by Goal












     Quick Explanation


    Quality check (cluster-randomized outcomes) — cannot be completed from the provided dataset

    The only typhoid-related evidence provided here is a 1998 international meta-analysis of efficacy & toxicity trials, not a cluster-randomized outcomes synthesis dataset. Therefore, a true “cluster-randomized outcomes quality check” (e.g., risk-of-bias per trial, ICC handling, effect on aggregated outcomes) cannot be computed without additional cluster-randomized trial reports.




     Long Explanation


    Meta-analysis: “Vi typhoid vaccine — cluster-randomized outcomes” quality check

    Evidence constraint: the provided sources include a typhoid meta-analysis of efficacy & toxicity across trial types, but do not include a cluster-randomized trial dataset of Vi vaccine outcomes suitable for a formal cluster-randomization QC.

    What is known from the provided typhoid evidence (Vi efficacy & duration)

    A BMJ meta-analysis reports estimated 3-year efficacy and protection duration for Vi (capsular) vaccine.

    Why a “cluster-randomized outcomes QC” cannot be computed from what we have

    A rigorous cluster-RCT QC typically requires, at minimum: the unit of randomization (cluster), the analysis accounting for intra-cluster correlation (ICC) or design effect, and effect estimates with appropriate standard errors.

    None of the provided typhoid source text includes a cluster-randomized Vi trial set or any ICC/design-effect inputs. The provided BMJ paper is an international meta-analysis summarizing efficacy/toxicity across trials, and the provided methodological critiques discuss meta-analysis quality generally but do not supply cluster-specific trial effect data.

    Provided methodological context: meta-analysis quality is often suboptimal

    In a systematic review of vaccinology meta-analyses (1991–2007), the median Oxman–Guyatt quality score was 3/7, and many meta-analyses had “extensive flaws”. This is directly relevant to why we must be cautious when interpreting pooled estimates.

    Skeptical QC checklist tailored to “Vi cluster-randomized outcomes”

    Since we lack cluster-RCT outcome inputs here, the checklist below indicates exactly what would be required to actually run the QC.

    QC domain Minimum data needed Status with provided sources
    Unit of randomization Cluster IDs, cluster assignment counts, number of clusters per arm Missing (not provided)
    ICC / design effect handling ICC estimate or SE inflation method; or adjusted effect + SE Missing (not provided)
    Outcome definition & adjudication Vi-specific outcomes (e.g., culture-confirmed typhoid), diagnostic methods, follow-up windows Not available as cluster-trial dataset
    Risk-of-bias details Blinding, allocation concealment, missingness, selective reporting disclosures Not available for cluster-RCTs here
    Meta-analysis method Model choice (random/fixed), heterogeneity stats, publication-bias assessment General meta-analysis quality concerns supported, but cluster-specific QC can’t be computed

    Confidence & falsifiability

    • Known: The provided BMJ meta-analysis reports approximate Vi efficacy and duration summaries (3-year efficacy ~55%; duration ~2 years).
    • Uncertain: Any “cluster-randomized outcomes QC” for Vi cannot be executed without the actual cluster-randomized trial-level data or at least effect estimates with cluster-adjusted variance.
    • How to disprove: Provide cluster-RCT reports (or extracted effect estimates with ICC/design effects) showing materially different Vi outcome effects than those implied by the pooled efficacy summary, or demonstrating that the pooled estimate fails cluster-adjustment requirements.

    Next steps inside BGPT

    Run an automated analysis agent to search/assemble the missing cluster-RCT outcome inputs (if available in BGPT’s paper database) and then compute an actual cluster-QC.



    Feedback:    

    Updated: May 01, 2026

     Top Data Sources ExportMCP


     Analysis Wizard



    It will compile Vi typhoid trial records into a cluster-aware dataset, extract effect sizes/SEs, infer missing design effects when possible, then compute QC metrics and sensitivity re-meta-analyses from retrieved trial reports.



     Hypothesis Graveyard


    A single-study “hero trial” explains most of the Vi pooled efficacy: unlikely here because the provided BMJ synthesis explicitly notes heterogeneity across trials; without trial-level weights we can’t confirm any single-trial dominance.


    Vi’s short duration (~2 years) is purely a statistical artifact of pooling non-uniform follow-up: falsification would require showing that duration estimates remain stable after restricting to trials with matched follow-up and case definitions.

     Science Art


    Meta-analysis: Vi typhoid vaccine cluster-randomized outcomes quality check Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending